The treatment of coronary heart disease: An update - Part 3: Statins beyond cholesterol lowering

Current Medical Research and Opinion

Volumn 17, Issue 1, 2001, Pages 34-37

  Kolovou, G ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Endothelial function; Haemostasis; Statins; Vascular smooth muscle; Vessel wall

Indexed keywords

LOW DENSITY LIPOPROTEIN; PRAVASTATIN; STATIN;

BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CONFERENCE PAPER; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; PROPHYLAXIS; RISK FACTOR; TREATMENT PLANNING; VASCULAR ENDOTHELIUM;

BLOOD VESSELS; CARDIOVASCULAR DISEASES; CHOLESTEROL; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE;

EID: 11244264708     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990152005324     Document Type: Conference Paper

References (41)

1. Current perspectives on statins
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
3. Effects of monotherapy with an HMG-CoA reductose inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian coronary atherosclerosis intervention trial
4. The effect of pravastatin on coronary events after myocardial infarction in patients with overage cholesterol levels
5. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: A report of the Regression Growth Evaluation Statin Study (REGRESS)
6. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
7. Disease free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: Report from the Program on the Surgical Control of the Hyperlipidemias (POSCH)
8. Systemic nature of endothelial dysfunction in atherosclerosis
9. Preduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
10. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
11. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease
12. Stability and instability: Two faces of coronary atherosclerosis
13. HMC-CoA reductase inhibitors: In vitro effects on carotid intimal thickening in normocholesterolemic rabbits
14. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types
15. Hyperlipidemia and coronary disease: Correction of increased thrombogenic potential with cholesterol reduction
16. Platelet-dependent thrombin generation in patients with hyperlipidemia
17. Mechanisms modifying atherosclerotic disease - From lipids to vascular biology
18. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia
19. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia
20. Lowering fibrinogen levels; clinical update
21. Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infraction
22. Hypercoagulable state in patients with hypercholesterolemia: Effects of pravastatin
23. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease
24. HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels
25. Effect of simvastatin on Lp(a) concentrations
26. Metalloproteases in remodeling of vascular extracellular matrix
27. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
28. Antiatherothrombotic properties of statins
29. Atheroma morphology and mechanical strength. Looks are important after all - Lose the fat
30. Low-density lipoprotein-independent effects of statins
31. Mechanisms of disease - Atherosclerosis - An inflammatory disease
32. Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects
33. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte derived macrophages
34. Reduced susceptibility of a low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
35. Atorvastatin and gemifibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
36. State-of-the art update and review: Clinical trials of lipid-lowering agents
37. Response of high-density lipoproteins to hypolipidemic drugs according to their initial level
38. Update in preventive medicine
39. Beyond lipids - The role of the endothelium in coronary artery disease
40. Cholesterol lowering and endothelial function
41. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial